Cognition Therapeutics announces patent extending zervimesine protection through 2045
CGTX•Cognition Therapeutics said a composition-of-matter patent for zervimesine expires in 2045 and may be extended by up to five years upon FDA approval. An FDA meeting for its DLB program is scheduled for next week, with manufacturing planned for Q1 2027.
1. Patent and program updates
Cognition Therapeutics announced issuance of a composition-of-matter patent for zervimesine (CT1812), expiring in 2045 and potentially extendable by up to five years upon FDA approval. The company said an FDA meeting for its DLB program is scheduled for next week and manufacturing is planned for Q1 2027.
